1 Big Winner and 1 Loser From the Upcoming Anthropic IPO
These two companies could move in different directions over the medium term.
The imminent Anthropic IPO has the potential to create two distinct outcomes for other companies within the artificial intelligence sector. One notable beneficiary may be Broadcom, a semiconductor specialist, while Recursion Pharmaceuticals could face significant challenges. Broadcom stands to gain from Anthropic's massive AI infrastructure investment, as the company designs custom AI chips and has already partnered with industry giants like Alphabet and Meta Platforms.
Their five-year, $161.2 billion agreement to provide Tensor Processing Unit (TPU)-based compute capacity to Anthropic further solidifies their relationship. This partnership could lead to additional agreements, especially as Anthropic's revenue continues to soar after its public debut. On the other hand, Recursion Pharmaceuticals, a clinical-stage biotech seeking to revolutionize drug discovery through AI, faces substantial hurdles.
Despite their claims of superiority, they still lack a single market-approved drug, and their AI-powered operating system has yet to demonstrate its value. As AI becomes increasingly integrated into drug discovery among both large and small pharmaceutical companies, Recursion's competitive advantage is expected to fade, rendering the company a risky investment.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
